Lopermid

Quick links to important sections

Lopermid

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lopermid

What is Lopermid?

Lopermid is a medicinal product used for the symptomatic treatment of various forms of diarrhea. It belongs to a group of medications known as antimotility agents, which work by slowing down the physical movement of the intestines.

Mechanism of Action

The active substance in Lopermid acts on the opioid receptors located in the muscular wall of the intestine. By binding to these receptors, the medication decreases peristalsis—the wave-like contractions that move food and waste through the digestive tract.

This slowing of intestinal transit time allows the body more time to absorb water and electrolytes from the stool. As a result, the consistency of the stool becomes firmer and the frequency of bowel movements is reduced.

Therapeutic Use

Lopermid is primarily utilized for the management of sudden, short-lived attacks of diarrhea (acute diarrhea). It may also be used in certain long-term conditions where chronic diarrhea is present, helping to stabilize bowel function and improve patient comfort by reducing urgency.

While the medication addresses the symptoms of diarrhea by changing how the gut moves, it does not treat the underlying cause of the condition, such as infection or inflammation. It is intended to provide relief from the discomfort and dehydration risks associated with loose stools.

What side effects are possible with Lopermid?

Officially Documented Adverse Reactions and Frequencies

The safety profile for loperamide hydrochloride (Lopermid) is organized by regulatory agencies based on the body system affected (System-Organ Class) and the statistical frequency of occurrence, such as Common (1 to 10 users in 100) or Rare (1 to 10 users in 10,000).

Common Adverse Reactions

System-Organ Class Reactions
Nervous System Disorders Headache, Dizziness
Gastrointestinal Disorders Constipation, Nausea, Flatulence

Rare Adverse Reactions

Rare effects documented include serious skin reactions (e.g., bullous eruptions such as Stevens-Johnson syndrome) and severe allergic events (anaphylactic shock). Other rare effects include loss of consciousness, stupor, miosis (pinpoint pupils), and urinary retention.


Serious Adverse Reactions and Safety Constraints

Government regulatory warnings highlight rare, serious risks primarily associated with misuse, overdose, or underlying conditions.

  • Cardiac Risks: Serious cardiac events, including QT interval prolongation, Torsades de Pointes, and cardiac arrest, have been documented, mainly when the drug is used at higher than recommended doses.
  • Gastrointestinal Complications: Due to its action, Lopermid carries a risk of severe intestinal issues, including paralytic ileus, megacolon, and toxic megacolon. The medicine must be immediately discontinued if constipation, abdominal distension, or ileus develops.

Population-Specific Safety Notes

  • Pediatric Patients: Lopermid is contraindicated in children under 2 years of age due to the heightened risk of serious respiratory depression and cardiac adverse reactions.
  • Hepatic Impairment: Caution is required in patients with liver problems as this may increase the systemic exposure and risk of central nervous system (CNS) toxicity.
  • Fluid and Electrolyte Depletion: The regulatory label specifies that use of loperamide does not substitute the essential need for fluid and electrolyte replacement in patients with diarrhea.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Overdose of Loperamide hydrochloride is officially documented to affect the Central Nervous System (CNS), respiratory, and cardiovascular systems. Manifestations include severe CNS depression (such as stupor or drowsiness), miosis (pinpoint pupils), respiratory depression, and an exaggerated inhibition of gut motility resulting in paralytic ileus or abdominal distension. The regulatory profile also lists urinary retention as a potential sign.


Severe Outcomes and Emergency Actions

The primary life-threatening risks associated with high-dose exposure or abuse are serious ventricular arrhythmias, including Torsades de Pointes ( TdP) and potential cardiac arrest. Because of these severe outcomes, regulatory authorities require that individuals seek immediate medical attention and contact emergency services immediately if an overdose is suspected. Immediate hospitalization is generally required for proper assessment. Children (particularly those under two years of age) are specifically noted in regulatory documentation to be highly susceptible to severe CNS and respiratory depression.


Management and Monitoring

Naloxone is designated as the specific antidote to reverse the CNS depression component of the toxicity; however, repeated doses may be necessary due to the drug’s prolonged action. Due to the risk of delayed cardiac events, ECG monitoring (cardiac monitoring) and extended observation are officially mandated, often for a minimum of mathbf48 hours, as part of the overall management plan.

Therapeutic Uses of Lopermid

Quick Facts

  • Lopermid is used for the symptomatic management of acute diarrhea.
  • Lopermid may be used to manage ongoing diarrhea related to inflammatory bowel disease.
  • Lopermid helps to reduce the volume of discharge from ileostomies.

What Lopermid treats: main uses and benefits

Lopermid is intended for the symptomatic management of diarrhea. Its main uses are focused on helping to address loose and frequent bowel movements.

This medication is often utilized to help control acute, nonspecific diarrhea, which may include travelers' diarrhea. For those with ongoing gastrointestinal concerns, Lopermid offers symptomatic relief from chronic diarrhea associated with inflammatory bowel disease.

A further therapeutic role involves supporting individuals following specific surgeries. Specifically, Lopermid may be used to aid in reducing the volume of discharge observed in patients with ileostomies. This use is part of a comprehensive plan to support gastrointestinal function and fluid balance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Loperamide? — Official Regulatory Information

This section outlines the eligibility and exclusion criteria for loperamide use, strictly based on authoritative government regulatory documents.


Populations and Conditions Excluded from Use (Contraindications)

Loperamide is contraindicated and must not be used by individuals with a known hypersensitivity to the drug or its components. It is also prohibited for patients experiencing acute dysentery (characterized by bloody stools and high fever), acute ulcerative colitis, or diarrhea caused by invasive bacterial organisms (e.g., Salmonella, Shigella).

Use is forbidden when inhibition of peristalsis must be avoided due to risk of serious complications, and it must be discontinued immediately if constipation or abdominal distension develops. It is strictly contraindicated in children under 2 years of age due to the risk of severe adverse events.


Populations Requiring Caution or Restricted Use

Age: For children between 2 and 12 years, use is generally restricted and requires medical supervision.

Organ Function: Patients with hepatic impairment should use loperamide with caution due to reduced metabolism, which may increase the risk of side effects.

Maternal Status: The medicine is not generally recommended for women who are pregnant or breastfeeding as safety has not been fully established, and small amounts may pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lopermid (loperamide hydrochloride) has officially documented interaction patterns primarily concerning its metabolic clearance and potential for additive pharmacodynamic effects. These patterns are based on regulatory labeling and interaction studies.

Pharmacokinetic Interactions

Loperamide is a substrate for metabolism by Cytochrome P450 (CYP) enzymes, specifically CYP3A4 and CYP2C8, and the efflux transporter P-glycoprotein (P-gp). Co-administration with inhibitors of these pathways is documented to increase loperamide plasma concentrations (exposure). Specific interacting medicines cited in regulatory documents include the CYP/P-gp inhibitors Ritonavir, Quinidine, and Itraconazole, and the CYP2C8 inhibitor Gemfibrozil.

Pharmacodynamic Interactions

There is a documented risk of additive effects when Lopermid is taken with certain substances:

  • QT-prolonging drugs: Co-administration may result in an additive risk of QTc interval prolongation, increasing the potential for serious ventricular arrhythmias. This risk is officially noted to be heightened when loperamide is used at high doses.
  • CNS-active agents: Use with other CNS depressants may cause additive CNS depression, potentially increasing symptoms like drowsiness or tiredness.
  • Other motility inhibitors: Combination with other drugs that reduce intestinal motility, such as Eluxadoline, increases the risk of severe constipation-related adverse reactions.

Population-Specific Caution

Official labeling notes that hepatic impairment (liver disease) can decrease loperamide's first-pass metabolism, which subsequently enhances the potential for increased systemic exposure and related interactions.

Mechanism of Action

Loperamide's function is executed primarily through its highly selective agonism of peripheral mu-opioid receptors located on the nerve endings of the enteric nervous system (ENS). This molecular interaction suppresses the release of excitatory neurotransmitters, notably acetylcholine, which are necessary for the smooth muscle's coordinated contractile function.

This suppression of neuronal signaling leads to the inhibition of propulsive peristalsis, the muscular waves that drive contents through the bowel. The resulting increase in intestinal transit time allows for prolonged contact between luminal contents and the mucosal surface, which facilitates the reabsorption of water and electrolytes.

Loperamide also modulates fluid transport, partly via binding to secondary receptors and through Calmodulin inhibition, influencing ion dynamics at the cellular level. The drug is actively restricted from reaching the central nervous system by the P-glycoprotein efflux pump, ensuring its action remains localized to the gastrointestinal tract.

Dosage and Administration Information

Official Administration and Dosing Guidelines

Lopermid, containing loperamide hydrochloride, is a medication intended exclusively for oral administration, available in 2 mg capsules, tablets, and liquid solutions. The official labeled instructions define different maximum doses and usage patterns based on the context of the condition and level of supervision.


Use Context Adult Initial Dose Subsequent Dosing & Maximum
Acute Diarrhea (OTC) 4 mg (two 2 mg units) 2 mg after each subsequent unformed stool; Max 8 mg per 24 hours
Chronic Diarrhea (Prescription) 4 mg daily 2 mg after each unformed stool, then reduced to 4 mg to 8 mg daily maintenance dose; Max 16 mg per 24 hours

Frequency and Duration: For acute episodes, subsequent doses are symptom-dependent (taken only after a loose stool) rather than based on a fixed time schedule. Self-treatment for acute diarrhea should generally not exceed 48 hours (two days), and administration must be discontinued if clinical improvement is not seen within this period. For chronic conditions, the established daily maintenance amount may be taken as a single dose or in divided doses. The medicine can be taken with or without food.

Special Populations: No dose adjustment is typically required for older adults or patients with renal impairment. However, the medication should be used with caution in the presence of hepatic impairment due to reduced metabolic clearance. Loperamide is not recommended for children under the age of 2 years; specific, weight-based liquid formulations are used for children aged 2 to 12 years under medical guidance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lopermid


The Research Base for Lopermid

The clinical information available for Lopermid (loperamide) is based on formal research studies, including randomized controlled trials (RCTs) and comprehensive meta-analyses. This body of evidence was studied for several conditions where managing symptoms of diarrhea is a primary goal. The research describes the patterns observed across different groups of people and contributes to highlighting what is known — and what is still uncertain about the medication's use in these contexts.


Evidence for Acute Non-Specific Diarrhea

Research exploring short-term symptom changes for acute, non-specific diarrhea primarily relies on short-term randomized controlled trials conducted during periods of increased symptom activity. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and episodic or acute changes.

Studies observed patterns where the measured duration of diarrhea and time to the last unformed stool (TLUS) in the studied groups was distinguishable from those who received a placebo. Studies described a pattern where lower stool frequency was measured over the initial 24 hours of administration across several trial cohorts. However, clinical trials routinely excluded people with conditions associated with higher risk, such as those with high fever or blood in the stool, meaning data for certain groups remain insufficient.


Evidence for Symptomatic Management of Chronic Diarrhea

For chronic diarrhea, studies explored the use of Lopermid for symptomatic evaluation. The research examined its use in observational settings evaluating daily-life functioning and included both RCTs and long-term observational cohorts. Findings describe patterns observed in the studies related to evaluating the overall frequency of bowel movements in patients with chronic conditions, such as Inflammatory Bowel Disease (IBD), but only when their condition was stable. The evidence is limited regarding changes to the underlying chronic disease course itself.


What Research Still Shows as Uncertain or Limited

Key limitations in the existing evidence base include the limited information for long-term outcomes across all uses, as well as the comparative evidence is lacking for all possible alternative treatments. The certainty remains low for patients with underlying infectious, high-fever, or bloody diarrheal episodes because these individuals are typically excluded from the main clinical trials. Studies help show what has been observed so far, but evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Lopermid (FAQ)


Q: How quickly does Lopermid usually start to work?

A: Studies examining the drug's activity indicate that Lopermid (loperamide) generally begins working within approximately one hour after a person takes an oral dose. This time frame represents the onset of action, which is when the medicine begins to slow down intestinal movement.


Q: How long can the effects of Lopermid typically last?

A: Information regarding the duration of effect for Lopermid is available in regulatory documents. The official pharmacological data indicates that the medicine has an apparent elimination half-life of around 10.8 hours, suggesting that the effects can potentially continue for up to a day or more.


Q: Can children or teenagers take Lopermid?

A: Regulatory bodies advise that Lopermid is not recommended for children who are under 2 years old. For children between the ages of 2 and 11, regulatory guidance indicates that use and dosing for children in this age range typically involves consultation with a healthcare professional. For those 12 and older, specific dosing guidelines for over-the-counter use are available.


Q: What happens if someone accidentally uses more Lopermid than recommended?

A: Official safety warnings highlight that taking more than the maximum amount directed can lead to serious heart problems, including life-threatening abnormal heart rhythms and sudden death. In situations where more than the directed amount is used, official information emphasizes the need to immediately contact emergency medical services or a poison control center.


Q: Are there any specific safety warnings for older adults using Lopermid?

A: Official documents generally state that no dose adjustment is typically needed for older adults. However, for elderly or frail patients experiencing acute diarrhea, regulatory information notes that a priority is preventing or reversing dehydration and loss of electrolytes (essential salts and minerals).


Q: Why does the official information mention heart-related risks for Lopermid?

A: Official warnings specifically mention heart-related risks because taking amounts of the medicine greater than those recommended can cause serious cardiac adverse events. These events can include dangerous heart rhythm issues. The risk is also emphasized when high amounts are reported to be combined with certain other medicines.


Q: Does Lopermid have a 'black box warning' in the US?

A: The US Food and Drug Administration (FDA) has issued a prominent warning, often referred to as a 'Black Box Warning,' for loperamide. This warning focuses on the serious risk of heart problems, including cardiac arrest and sudden death, associated with using high doses of the medication, particularly in cases of abuse or misuse.


Q: Is Lopermid recommended for travelers' diarrhea?

A: Yes, loperamide hydrochloride is officially approved by regulatory bodies for the management and symptomatic relief of different types of diarrhea, including that commonly referred to as Travelers' Diarrhea.


Q: Is Lopermid the same type of medicine as Pepto-Bismol?

A: No, Lopermid (loperamide) and Pepto-Bismol (bismuth subsalicylate) are classified as different types of medicines. Loperamide is an antidiarrheal agent that works by slowing down the movement of the intestines. Bismuth subsalicylate works through different mechanisms and is also classified as an anti-ulcer agent.


Q: What is the difference between Lopermid and Loperamide?

A: Loperamide is the official name for the active pharmaceutical ingredient that performs the function of controlling diarrhea symptoms. Lopermid is one of the brand names under which this active ingredient, loperamide hydrochloride, is marketed and sold.


Q: Is Lopermid considered an antibiotic?

A: No, Lopermid (loperamide) is not classified as an antibiotic. It is officially categorized as an antidiarrheal agent, meaning its primary function is to relieve the symptoms of diarrhea, not to treat bacterial infections.


Q: Does Lopermid have a drowsy effect for most people?

A: Official product labeling states that tiredness, drowsiness, or dizziness may occur when using the product. Regulatory documents indicate that due to these possible effects, the ability to drive or operate machinery may be affected.


Q: What are the official guidelines regarding using Lopermid during pregnancy?

A: Official drug labeling advises that individuals who are pregnant or breastfeeding typically seek the guidance of a health professional prior to using the product.


Q: Is Lopermid available without a prescription?

A: Loperamide hydrochloride is widely available for purchase without a prescription for the symptomatic management of acute diarrhea. However, some higher doses used for treating chronic conditions may be restricted to prescription-only use.


Q: Are headaches a noted side effect of Lopermid?

A: Yes, headaches are listed in regulatory documents and official product summaries as one of the reported undesirable effects associated with the use of loperamide.


Q: How is Lopermid different from activated charcoal?

A: Lopermid (loperamide) is an antidiarrheal that works by reducing the speed of intestinal movement. Activated charcoal, conversely, is classified as an adsorbent agent that functions by binding to and potentially removing certain substances from the digestive tract.


Q: Is it true that Lopermid should not be taken for diarrhea with fever or blood?

A: Official product warnings state that the medicine is not intended for use if the user has bloody or black stools. Additionally, regulatory information suggests consulting a healthcare professional before use if a fever is present, as these symptoms can indicate a more serious condition.


Q: What if I miss a scheduled use of Lopermid?

A: Since Lopermid is often taken on an 'as needed' basis following an unformed stool, official information states that if a dose is missed, no action is usually necessary. However, if the medicine is being taken in a scheduled regimen for a chronic condition, use is typically managed under the direction of a prescriber.


Q: Is there a generic version of Lopermid available?

A: Yes, the active ingredient, loperamide hydrochloride, is widely available generically from numerous manufacturers. Generic versions contain the same active ingredient and meet the same regulatory standards as the brand-name product.


Q: Where can I find the official prescribing information (package insert) for Lopermid?

A: The official product information, such as the prescribing information or Summary of Product Characteristics (SmPC), is publicly available on government websites. You can typically find this on authoritative sites like the FDA DailyMed or resources provided by the European Medicines Agency (EMA).


Q: What is the general recommended period for using Lopermid?

A: For the self-treatment of acute diarrhea, regulatory documents generally advise that the medicine should not be used for a period longer than 2 days. If symptoms persist or worsen after 48 hours, it is advised that the product be discontinued.


Q: Is Lopermid related to opioids in any way?

A: Loperamide is classified chemically as a synthetic opioid derivative. It is intended to act primarily on opioid receptors located in the intestine to control diarrhea symptoms, and not on the central nervous system, which is where traditional opioid pain relievers act.


Q: Does Lopermid treat the cause of diarrhea or just the symptoms?

A: Official regulatory documents describe the purpose of Lopermid as controlling and relieving the symptoms of diarrhea. It functions by slowing down the movement of the gut, but it is not intended to address the underlying cause of the diarrhea itself.


Q: Is Lopermid approved in countries outside of the US?

A: Yes, the active ingredient loperamide hydrochloride is approved and regulated by governmental health authorities in many regions outside of the US, including those in the UK, Canada, and the European Union.


Q: What kind of studies have been performed on Lopermid?

A: Regulatory overviews cite a history of clinical trials, including double-blind, controlled studies, which formed the basis for the drug's approval for both acute and chronic diarrhea.


Q: What are the non-active ingredients in Lopermid tablets or capsules?

A: Official product labeling lists the inactive ingredients, which are components necessary for the formulation but do not have a medical effect. These may include common excipients like magnesium stearate, lactose, or cellulose, but they can vary depending on the specific manufacturer and product.


Q: Can Lopermid be split or crushed?

A: Depending on the specific form of the medicine (e.g., tablet versus capsule), some official guidelines may suggest that loperamide can be split or crushed. However, clarification with a pharmacist or prescriber is typically required, as specific formulations may not be intended for alteration.


Q: Are there any specific diet changes recommended while using Lopermid?

A: Product directions do not specify particular diet changes related to the drug's function, but they emphasize the importance of fluid intake. Official sources advise drinking plenty of clear fluids to help replace the fluids and salts that are often lost due to diarrhea.


Q: What is the meaning of 'acute' in relation to the use of Lopermid?

A: In regulatory documents, the term 'acute' diarrhea is used to refer to a condition that is sudden in onset and typically short-lived. In the context of self-medication, acute diarrhea is generally expected to resolve within 48 hours.

How should Lopermid be stored and disposed of?

How to Store and Dispose of Loperamide

Official regulatory labeling dictates strict conditions for the storage and disposal of loperamide hydrochloride to maintain its stability.

Storage Requirements

Loperamide must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. It is mandatory to protect the product from light and moisture and to avoid excessive heat above 40 C. The medicine must be kept in its closed, original container and should not be used if the blister packaging is torn or broken. As a non-negotiable safety rule, the product must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired loperamide product and waste material must be disposed of in accordance with local regulatory requirements. This often involves returning the product to a pharmacy take-back program to prevent discharge into household waste or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lopermid found in:

A-Z Index: